Japanese hospitals adopt more generics

29 March 2009

In response to a request from Japan's Ministry of Health, Labor and Welfare, the National Hospital Organization - governing 145 national  hospitals - disclosed the list of its adopted generic drugs on its web  site as well as the national medical centers including the National  Cancer Center and National Cardiovascular Center did (Marketletter  March 2).

According to the NHO, these hospitals have adopted 2,082 generic  medicines in total, in addition to 4,088 branded products. The  Organization said the Pharmaceuticals Affairs Committee of each  national hospital is deciding whether it will adopt copycat drugs after  confirming their quality, as well as the supply and  information-providing systems of generic drugmakers.

The MHLW expects that the further adoption of generic drugs by national  hospitals and medical centers will facilitate the use of such products  among other public and private medical hospitals throughout the  nation.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight